Afinitor approved for advanced breast cancer

Afinitor approved for advanced breast cancer

(HealthDay) -- Afinitor (everolimus) has been approved in combination with the drug exemestane to treat postmenopausal women with advanced hormone-receptor positive, HER2-negative breast cancer, the U.S. Food and Drug Administration said Friday.

The newly approved combination is sanctioned for women whose cancer has progressed or returned despite previous use of the drugs letrozole (Femara) or anastrozole (Arimidex), the agency said in a news release.

Afinitor -- already sanctioned for uses which include treating certain forms of advanced -- was clinically evaluated for the new use among 724 people with . People who took the combination drug had a 4.6-month improvement in the average time to disease progression or death, compared to those who took a placebo.

The most common side effects among those taking Afinitor were mouth ulcers, infection, rash, fatigue, diarrhea, and loss of appetite.

Afinitor is marketed by Novartis, based in East Hanover, N.J.

More information: The National Cancer Institute has more about breast cancer.


add to favorites email to friend print save as pdf

Related Stories

Perjeta approved for advanced breast cancer

Jun 11, 2012

(HealthDay) -- Perjeta (pertuzumab) has been approved by the U.S. Food and Drug Administration to treat people with HER2-positive late-stage breast cancer, the agency said in a news release.

Recommended for you

Breakthrough to take the pain out of catheters

11 hours ago

A new pharmaceutical product that could significantly improve quality of life for catheter users all over the world is to be developed by Queen's University Belfast after it won a national award.

FDA warning: men's testosterone drugs overused (Update)

Mar 03, 2015

The Food and Drug Administration is warning doctors against over-prescribing testosterone-boosting drugs for men, saying the popular treatments have not been established as safe or effective for common age-related ...

User comments

Please sign in to add a comment. Registration is free, and takes less than a minute. Read more

Click here to reset your password.
Sign in to get notified via email when new comments are made.